Literature DB >> 18684915

Cutting edge: in vivo trogocytosis as a mechanism of double negative regulatory T cell-mediated antigen-specific suppression.

Megan S Ford McIntyre1, Kevin J Young, Julia Gao, Betty Joe, Li Zhang.   

Abstract

Recent data have demonstrated that treatment with alphabeta-TCR(+)CD3(+)CD4(-)CD8(-)NK1.1(-) double negative (DN) regulatory T cells (Tregs) inhibits autoimmune diabetes and enhances allotransplant and xenotransplant survival in an Ag-specific fashion. However, the mechanisms whereby DN Tregs suppress Ag-specific immune responses remain largely unknown. In this study, we demonstrate that murine DN Tregs acquire alloantigen in vivo via trogocytosis and express it on their cell surface. Trogocytosis requires specific interaction of MHC-peptide on APCs and Ag-specific TCR on DN Tregs, as blocking this interaction prevents DN Treg-mediated trogocytosis. Acquisition of alloantigen by DN Tregs was required for their ability to kill syngeneic CD8(+) T cells. Importantly, DN Tregs that had acquired alloantigen were cytotoxic toward Ag-specific, but not Ag-nonspecific, syngeneic CD8(+) T cells. These data provide new insight into how Tregs mediate Ag-specific T cell suppression and may enhance our ability to use DN Tregs as a therapy for transplant rejection and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684915     DOI: 10.4049/jimmunol.181.4.2271

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

Review 1.  Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions.

Authors:  Stephen C Juvet; Li Zhang
Journal:  J Mol Cell Biol       Date:  2012-02       Impact factor: 6.216

Review 2.  Biting Off What Can Be Chewed: Trogocytosis in Health, Infection, and Disease.

Authors:  Akhila Bettadapur; Hannah W Miller; Katherine S Ralston
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

3.  Isolation of double negative αβ T cells from the kidney.

Authors:  Maria N Martina; Samantha Bandapalle; Hamid Rabb; Abdel R Hamad
Journal:  J Vis Exp       Date:  2014-05-16       Impact factor: 1.355

4.  Apple polyphenols require T cells to ameliorate dextran sulfate sodium-induced colitis and dampen proinflammatory cytokine expression.

Authors:  Jerod A Skyberg; Amy Robison; Sarah Golden; Maryclare F Rollins; Gayle Callis; Eduardo Huarte; Irina Kochetkova; Mark A Jutila; David W Pascual
Journal:  J Leukoc Biol       Date:  2011-06-21       Impact factor: 4.962

5.  Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.

Authors:  Srinivas S Somanchi; Anitha Somanchi; Laurence J N Cooper; Dean A Lee
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

Review 6.  Advances on Non-CD4 + Foxp3+ T Regulatory Cells: CD8+, Type 1, and Double Negative T Regulatory Cells in Organ Transplantation.

Authors:  Ann J Ligocki; Jerry Y Niederkorn
Journal:  Transplantation       Date:  2015-08       Impact factor: 4.939

7.  Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease.

Authors:  Matthew R Olson; Steven M Varga
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

8.  Double negative (CD3+ 4- 8-) TCR alphabeta splenic cells from young NOD mice provide long-lasting protection against type 1 diabetes.

Authors:  Beverly Duncan; Cristina Nazarov-Stoica; Jacqueline Surls; Margaret Kehl; Constantin Bona; Sofia Casares; Teodor-D Brumeanu
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

Review 9.  Receptor-mediated T cell absorption of antigen presenting cell-derived molecules.

Authors:  Inkyu Hwang; DaLim Ki
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

Review 10.  Moving to tolerance: clinical application of T regulatory cells.

Authors:  Alicia N McMurchy; Andrew Bushell; Megan K Levings; Kathryn J Wood
Journal:  Semin Immunol       Date:  2011-05-28       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.